

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



February 13, 2025

Company Takara Bio Inc. (Securities code: 4974; Prime Market)
 Headquarters Nojihigashi 7-4-38, Kusatsu, Shiga, Japan
 Representative Koichi Nakao, President & CEO
 Contact Takuya Kakemi, Executive Officer, in charge of PR & IR Department
 Telephone (+81)77-565-6970
 Website <https://www.takara-bio.co.jp/>

Notice Concerning Revisions to the Financial Results Forecasts

Takara Bio Inc. hereby announces that in the light of the most recent operating trends, to revise the financial results forecasts for the fiscal year ending March 31, 2025 (April 1, 2024 – March 31, 2025), disclosed on May 10, 2024, as described below.

1. Revisions to financial results forecasts

Revisions to consolidated financial results forecasts for the full-year of the current fiscal year (April 1, 2024 through March 31, 2025)

	Net sales	Operating profit	Ordinary profit	Net income attributable to owners of the parent	Net income per share
	Million yen	Million yen	Million yen	Million yen	Yen
Previously announced forecasts (A) (Disclosed on May 10, 2024)	48,900	5,000	5,200	3,400	28.24
Revised forecasts (B)	45,500	3,000	3,000	1,000	8.30
Change (B-A)	(3,400)	(2,000)	(2,200)	(2,400)	-
Change (%)	(7.0)	(40.0)	(42.3)	(70.6)	-
(Reference) Actual consolidated results for the previous fiscal year (Fiscal year ended March 31, 2024)	43,505	3,003	3,405	1,480	12.30

(2) Reason for revision

Due to prolonged inflation in the U.S. and Europe and the economic recession in China and other factors, the market conditions in the life science research and development have further deteriorated, and price competition for products and services has also intensified. As a result, net sales in our Reagents and Instruments business and CDMO business are expected to be lower than the previous forecast. Accordingly, despite efforts to curb administrative expenses and other expenditures, each profit item is also expected to be lower than the previous forecast. Therefore, the full-year consolidated financial results forecasts announced on May 10, 2024 have been revised.

For a comparison of the revised consolidated financial forecasts with the previous fiscal year's result and the previous forecasts, please refer to the "Comparative Statement of Income Relating to Consolidated Financial Forecasts" on page 11 of the "Consolidated Financial Results for the Nine Months Ended December 31, 2024" announced today.

Forward-Looking Statements

Statements contained in these materials with respect to the Company's current plans, forecasts, strategies and beliefs that are not historical facts are forward-looking statements about the further performance of the Company and its consolidated subsidiaries. These statements are based on management's assumptions and beliefs in light of information currently available to it, but are based on a number of assumptions and beliefs derived from information that contains significant risks and uncertainties. Actual results may differ materially from these forecasts due to various factors. Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors' prices and product strategies, declines in selling power of the Company's existing and new products, disruptions to production, violations of our intellectual property rights, rapid advances in technology, and unfavorable verdicts in major litigation.